RegenCell BioScience Holdings (RGC)

[shinhari1309]

Company CEO/Philanthropist buys back RGC shares

RGC, a healthcare business that was targeted by shortsellers in Q2 22', is facing the full force of the company CEO.

According to the CEO's Schedule 13D filings with the SEC (US Securities and Exchange Commission), the CEO (Mr Au) spent $5.03 million of his own cash to buy ordinary shares on the open market between July 2021 and May 2022. Mr Au currently owns a total of 10,539,159 ordinary shares, accounting for nearly 81% of the company's total issued and outstanding ordinary shares.

The company's objective is to provide a natural treatment technique for neurocognitive disorders and degenerations, notably ADHD and ASD, as well as viral illnesses that impair people's immune systems, such as COVID-19.

Aside from RGC's approach to developing successful treatments for ADHD and ASD, Mr Au has also been involved in his own philanthropic project (within his own means) that aims to provide care to over 10,000 affected children with ADHD, ASD, and Covid-19, as well as those affected by financial difficulties. Mr Au's programme has already benefitted over 150 youngsters since its inception on April 16, 22.